A Phase I/II Study of Induction AMG 655 and Gemcitabine, Followed by AMG 655, Capecitabine and 3-D Conformal Radiation Therapy (3DCRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer.

Trial Profile

A Phase I/II Study of Induction AMG 655 and Gemcitabine, Followed by AMG 655, Capecitabine and 3-D Conformal Radiation Therapy (3DCRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs Conatumumab (Primary) ; Capecitabine; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Planned number of patients changed from 95 to 89 as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top